Pharmion Corp.

Robert J. Hugin has been a director since April 2003. Since May 2006, Mr. Hugin has served as the President and Chief Operating Officer of Celgene Corporation, a biopharmaceutical company focused on cancer and immunological diseases. From June 1999 to May 2006, Mr. Hugin served as the Senior Vice President and Chief Financial Officer of Celgene. From 1985 to 1999, Mr. Hugin held positions with J.P. Morgan & Co. Inc., an investment banking firm, serving most recently as a Managing Director. Mr. Hugin is a director of Celgene Corporation and Atlantic Health System, Inc. Mr. Hugin received an A.B. from Princeton University and an M.B.A. from the University of Virginia.

M. James Barrett, Ph.D. has served as a general partner of NEA Partners 10 Limited Partnership, the general partner of New Enterprise Associates 10 Limited Partnership, a venture capital fund, since August 2001. From January 1997 to August 2001, he served as Chairman and Chief Executive Officer of Sensors for Medicine and Science, Inc., a medical device company, which he founded in 1997. He continues to serve as the Chairman of its Board of Directors. Dr. Barrett also serves on the Boards of Directors of two publicly-held biopharmaceutical companies: Taragacept, Inc. and YM Biosciences, Inc., and the Boards of several privatelyheld biopharmaceutical companies. Dr. Barrett received a B.S. in Chemistry from Boston College, a Ph.D. in Biochemistry from the University of Tennessee and a M.B.A. from the University of Santa Clara.

Mr. Blair has been a General Partner of Domain Associates since its founding in 1985. He has over thirty years experience with venture and emerging growth companies. In the course of this experience, he has been involved with the creation and successful development as a board member of over forty life science ventures including Amgen, Amylin Pharmaceuticals, Applied Biosystems, Aurora Biosciences, Dura Pharmaceuticals, Sicor, and Molecular Dynamics. A former Managing Director of Rothschild Inc., Mr. Blair was directly involved at a senior level with Rothschild/New Court venture capital activities from 1978 to 1985. From 1969 to 1978, he was associated with F.S. Smithers and Company, and White Weld and Company, two investment banking firms actively involved with new ventures and emerging growth companies. From 1961 to 1969, Mr. Blair was an engineering manager with RCA during which time he received a David Sarnoff Fellowship. Mr. Blair is presently an Advisor to the Department of Molecular Biology at Princeton University, an Advisor to the Department of BioEngineering at the University of Pennsylvania, and he also serves on the Board of Directors of CapCure.

Jim Loughlin was named to the Celgene Board of Directors in January 2007, and serves as a member of the Audit Committee. Mr. Loughlin, an experienced corporate director served as the National Director of the Pharmaceuticals Practice at KPMG, including a five-year term as member of the Board of Directors of KPMG LLP. Additionally, Mr. Loughlin served as Chairman of the Pension and Investment Committee of the KPMG Board from 1995 through 2001. He also served as Partner in charge of Human Resources, Chairman of the Personnel and Professional Development Committee, Secretary and Trustee of the Peat Marwick Foundation and a member of the Pension, Operating and Strategic Planning Committees.

Array